GlaxoSmithKline joins Sosei's who's-who list of clients with global licensing pact for IBD small molecules

Big drugmakers are on the hunt for novel therapeutics in a range of ultra-competitive therapeutic areas. Japan’s Sosei Heptares has emerged in recent years as a sought-after partner for Big Pharmas seeking novel neuro candidates — but now GlaxoSmithKline wants to try the preclinical R&D expert’s work in inflammatory bowel disease.